ZA200610042B - Levodopa prodrugs, and compositions and uses thereof - Google Patents

Levodopa prodrugs, and compositions and uses thereof Download PDF

Info

Publication number
ZA200610042B
ZA200610042B ZA200610042A ZA200610042A ZA200610042B ZA 200610042 B ZA200610042 B ZA 200610042B ZA 200610042 A ZA200610042 A ZA 200610042A ZA 200610042 A ZA200610042 A ZA 200610042A ZA 200610042 B ZA200610042 B ZA 200610042B
Authority
ZA
South Africa
Prior art keywords
compound
phenyl
optionally substituted
furo
pyridin
Prior art date
Application number
ZA200610042A
Other languages
English (en)
Inventor
Xiang Jia-Ning
Mark A Gallop
Cindy X Zhou
Nguyen Mark
Dai Xuedong
Li Jianhua
Kenneth C Cundy
Nelson L Jumbe
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Publication of ZA200610042B publication Critical patent/ZA200610042B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
ZA200610042A 2004-06-04 2005-06-03 Levodopa prodrugs, and compositions and uses thereof ZA200610042B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57708704P 2004-06-04 2004-06-04

Publications (1)

Publication Number Publication Date
ZA200610042B true ZA200610042B (en) 2008-06-25

Family

ID=35063308

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200610042A ZA200610042B (en) 2004-06-04 2005-06-03 Levodopa prodrugs, and compositions and uses thereof

Country Status (21)

Country Link
US (5) US7342131B2 (US07342131-20080311-C00012.png)
EP (1) EP1751087B1 (US07342131-20080311-C00012.png)
JP (1) JP4781352B2 (US07342131-20080311-C00012.png)
KR (1) KR101287297B1 (US07342131-20080311-C00012.png)
CN (1) CN101023056B (US07342131-20080311-C00012.png)
AU (1) AU2005252220B2 (US07342131-20080311-C00012.png)
BR (1) BRPI0510776A (US07342131-20080311-C00012.png)
CA (1) CA2568632C (US07342131-20080311-C00012.png)
CY (1) CY1113077T1 (US07342131-20080311-C00012.png)
DK (1) DK1751087T3 (US07342131-20080311-C00012.png)
ES (1) ES2390126T3 (US07342131-20080311-C00012.png)
HK (1) HK1099927A1 (US07342131-20080311-C00012.png)
IL (1) IL179438A (US07342131-20080311-C00012.png)
MX (2) MX339690B (US07342131-20080311-C00012.png)
NO (1) NO20070035L (US07342131-20080311-C00012.png)
NZ (1) NZ551511A (US07342131-20080311-C00012.png)
PL (1) PL1751087T3 (US07342131-20080311-C00012.png)
PT (1) PT1751087E (US07342131-20080311-C00012.png)
RU (1) RU2365580C2 (US07342131-20080311-C00012.png)
WO (1) WO2005121069A1 (US07342131-20080311-C00012.png)
ZA (1) ZA200610042B (US07342131-20080311-C00012.png)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339690B (es) * 2004-06-04 2016-06-06 Xenoport Inc Profarmacos de levodopa y sus composiciones y usos.
US7323585B2 (en) 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US7563821B2 (en) * 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
JP4862994B2 (ja) * 2006-04-26 2012-01-25 日産化学工業株式会社 ２−（２−ヒドロキシエトキシ）イソインドリン−１，３−ジオン化合物の選択的製造方法
AU2007267135B2 (en) * 2006-05-31 2013-03-07 AbbVie Pharmaceuticals GmbH Long term 24 hour intestinal administration of levodopa/carbidopa
WO2008034087A2 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Treating schizophrenia with combinations of levodopa and an antipsychotic agent
JP2011502953A (ja) * 2006-12-21 2011-01-27 ゼノポート，インコーポレーテッド ジメチル置換されたレボドパジエステルのプロドラッグ、組成物及び使用方法
TW200843731A (en) * 2006-12-21 2008-11-16 Xenoport Inc Catechol protected levodopa diester prodrugs, compositions, and methods of use
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US9290445B2 (en) * 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
GB0904300D0 (en) * 2009-03-12 2009-04-22 Amarin Neuroscience Ltd Essential fatty acid compounds
US20120142720A1 (en) 2009-07-02 2012-06-07 Kempharm, Inc. Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Methods of Making and Use Thereof
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
JP2013520521A (ja) 2009-11-09 2013-06-06 ゼノポート，インコーポレーテッド レボドパプロドラッグの医薬組成物及び経口剤形並びに使用方法
BR112012018256A8 (pt) 2010-03-04 2017-12-19 Orion Corp método de tratamento de doença de parkinson
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
KR20130121902A (ko) 2010-12-02 2013-11-06 오노 야꾸힝 고교 가부시키가이샤 신규 화합물 및 그 의약 용도
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
CN104350041A (zh) 2012-05-07 2015-02-11 塞利克斯比奥私人有限公司 用于治疗神经系统疾病的组合物和方法
AU2013257742A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
CA2873096A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2873098A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
WO2014037834A2 (en) 2012-09-08 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of inflammation and lipid disorders
UA114661C2 (uk) 2012-12-28 2017-07-10 Дау Аґросаєнсиз Елелсі Синергічні фунгіцидні суміші для боротьби з грибковими хворобами злаків
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
MX2015017253A (es) 2013-06-13 2016-04-19 Veroscience Llc Composiciones y metodos para tratar trastornos metabolicos.
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016110865A1 (en) 2015-01-06 2016-07-14 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and pain
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
CN111454290B (zh) * 2014-10-21 2022-12-23 艾伯维公司 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
KR20190049944A (ko) 2014-11-25 2019-05-09 켐팜 인코포레이티드 옥시코돈의 벤조산, 벤조산 유도체 및 헤테로아릴 카르복실산 콘쥬게이트
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
EP3240409A4 (en) 2014-12-30 2018-06-20 Dow Agrosciences LLC Picolinamides with fungicidal activity
KR20170100550A (ko) 2014-12-30 2017-09-04 다우 아그로사이언시즈 엘엘씨 살진균 활성을 갖는 피콜린아미드 화합물
EP3240420A4 (en) 2014-12-30 2018-07-11 Dow Agrosciences LLC Use of picolinamide compounds with fungicidal activity
CR20220034A (es) 2014-12-30 2022-02-11 Dow Agrosciences Llc Compuestos de picolinamida con actividad fungicida (divisional 2017-0308)
JP2018500361A (ja) 2014-12-30 2018-01-11 ダウ アグロサイエンシィズ エルエルシー 殺真菌剤としてのピコリンアミドの使用
CA2984494A1 (en) * 2015-05-06 2016-11-10 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
JP2019515908A (ja) * 2016-04-20 2019-06-13 アッヴィ・インコーポレイテッド カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
TW201842851A (zh) 2017-05-02 2018-12-16 美商陶氏農業科學公司 用於穀類中的真菌防治之協同性混合物
TWI774761B (zh) 2017-05-02 2022-08-21 美商科迪華農業科技有限責任公司 用於穀物中的真菌防治之協同性混合物
CA3062074A1 (en) 2017-05-02 2018-11-08 Dow Agrosciences Llc Use of an acyclic picolinamide compound as a fungicide for fungal diseases on turfgrasses
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
JP6770692B2 (ja) * 2017-12-27 2020-10-21 株式会社タンガロイ 超硬合金及び被覆超硬合金
BR102019004480B1 (pt) 2018-03-08 2023-03-28 Dow Agrosciences Llc Picolinamidas como fungicidas
BR112021006669A2 (pt) 2018-10-15 2021-07-06 Dow Agrosciences Llc métodos para síntese de oxipicolinamidas

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962414A (en) * 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) * 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US3983138A (en) 1973-09-25 1976-09-28 Merck & Co., Inc. Amino acid esters
US4038411A (en) * 1973-09-25 1977-07-26 Merck & Co., Inc. Antihypertensive amino acid esters
DD116454A5 (US07342131-20080311-C00012.png) * 1973-09-25 1975-11-20
US3992518A (en) * 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4035593A (en) * 1975-10-09 1977-07-12 Northern Engraving Company, Inc. Flexible pressure sensitive switch actuator module adaptable to a keyboard surface having fixed contact array
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) * 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) * 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
FR2365341A1 (fr) * 1976-09-28 1978-04-21 Synthelabo Derives de l'acide l-(phenyl-3 amino-2 propionyloxy)-2 acetique
US4180509A (en) * 1977-07-01 1979-12-25 Merrell Toraude Et Compagnie α-Ethynyl tryptophanes
US4311706A (en) 1980-01-22 1982-01-19 Interx Research Corporation Novel dopa/dopamine prodrugs
JPS5824547A (ja) 1981-08-06 1983-02-14 Nippon Zoki Pharmaceut Co Ltd 新規アミノ酸誘導体
JPS5824347A (ja) 1981-08-06 1983-02-14 Ube Ind Ltd オレフイン酸化用触媒の製法
US4914222A (en) * 1983-08-29 1990-04-03 Merck & Co., Inc. Crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters and process
NZ209285A (en) * 1983-08-29 1988-04-29 Merck & Co Inc Crystalline salts of (r,s)-1-pivaloyloxyethyl (s)-3-(3,4-dihydroxyphenyl)-2-methylalaninate with oxygenated acids, and pharmaceutical compositions
LU85757A1 (fr) * 1985-02-04 1986-09-02 Univ Catholique Louvain Derives nouveaux de la l-dopa,procedes pour leur preparation et compositions pharmaceutiques concernant de tels composes
US4873263A (en) * 1985-12-30 1989-10-10 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4663349A (en) 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4771073A (en) * 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
DE3779500T2 (de) 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
DK406686D0 (da) * 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5332576A (en) * 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
US5840756A (en) 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
US20020102291A1 (en) 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
EP1358200A4 (en) * 2000-10-06 2005-07-20 Xenoport Inc COMPOUNDS DERIVED FROM GALLENIC ACID TO IMPROVE THE ORAL ABSORPTION AND SYSTEMIC BIOVERABILITY OF MEDICAMENTS
US20020151526A1 (en) 2000-10-06 2002-10-17 Gallop Mark A. Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism
IL159812A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
AU2002340470A1 (en) * 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
WO2004052841A1 (en) * 2002-12-06 2004-06-24 Xenoport, Inc. Carbidopa prodrugs and uses thereof
US20050209181A1 (en) * 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
MX339690B (es) * 2004-06-04 2016-06-06 Xenoport Inc Profarmacos de levodopa y sus composiciones y usos.
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
DE102005022276A1 (de) 2005-05-13 2006-11-16 Ellneuroxx Ltd. Derivate von Dihydroxyphenylalanin
US7563821B2 (en) * 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US9603941B2 (en) 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
WO2008034087A2 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Treating schizophrenia with combinations of levodopa and an antipsychotic agent
TW200843731A (en) 2006-12-21 2008-11-16 Xenoport Inc Catechol protected levodopa diester prodrugs, compositions, and methods of use
JP2011502953A (ja) 2006-12-21 2011-01-27 ゼノポート，インコーポレーテッド ジメチル置換されたレボドパジエステルのプロドラッグ、組成物及び使用方法
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US9290445B2 (en) 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
JP2013520521A (ja) 2009-11-09 2013-06-06 ゼノポート，インコーポレーテッド レボドパプロドラッグの医薬組成物及び経口剤形並びに使用方法

Also Published As

Publication number Publication date
EP1751087B1 (en) 2012-06-27
CA2568632C (en) 2013-06-25
US7534813B2 (en) 2009-05-19
NO20070035L (no) 2007-02-01
US20050282891A1 (en) 2005-12-22
PL1751087T3 (pl) 2012-11-30
CA2568632A1 (en) 2005-12-22
US20090137834A1 (en) 2009-05-28
AU2005252220A1 (en) 2005-12-22
EP1751087A1 (en) 2007-02-14
US8163958B2 (en) 2012-04-24
MXPA06014132A (es) 2007-03-07
WO2005121069A1 (en) 2005-12-22
DK1751087T3 (da) 2012-07-16
JP4781352B2 (ja) 2011-09-28
RU2365580C2 (ru) 2009-08-27
US20120190861A1 (en) 2012-07-26
NZ551511A (en) 2010-09-30
CY1113077T1 (el) 2016-04-13
IL179438A (en) 2013-12-31
US7342131B2 (en) 2008-03-11
US20110201817A1 (en) 2011-08-18
PT1751087E (pt) 2012-09-10
IL179438A0 (en) 2007-05-15
US20080132570A1 (en) 2008-06-05
KR101287297B1 (ko) 2013-07-23
AU2005252220B2 (en) 2011-06-02
BRPI0510776A (pt) 2007-11-20
JP2008501704A (ja) 2008-01-24
ES2390126T3 (es) 2012-11-06
US20100197953A9 (en) 2010-08-05
CN101023056A (zh) 2007-08-22
MX339690B (es) 2016-06-06
CN101023056B (zh) 2011-05-25
US7956212B2 (en) 2011-06-07
RU2006141416A (ru) 2008-05-27
HK1099927A1 (en) 2007-08-31
KR20070039029A (ko) 2007-04-11

Similar Documents

Publication Publication Date Title
ZA200610042B (en) Levodopa prodrugs, and compositions and uses thereof
JP4824551B2 (ja) 化合物
AU754734B2 (en) Indazole bioisostere replacement of catechol in therapeutically active compounds
US7456187B2 (en) Furanopyrimidine compounds as potassium ion channel inhibitors
CA2779073C (en) Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
CA2993304C (en) Novel compounds as ror gamma modulators
NZ505845A (en) Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
JP4955557B2 (ja) カリウムチャネル阻害剤として有効なフラノピリミジン化合物
EA024702B1 (ru) Новые иммуномодуляторные и противовоспалительные соединения
US20080306107A1 (en) Compounds
ES2324536T3 (es) Derivados de tienopirimidina como inhibidores de los canales de potasio.
AU2010281503B2 (en) Novel azaheterocyclic compounds
MX2015002887A (es) Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
KR20160095117A (ko) 페닐-트리아졸로-피리딘 화합물
KR20160077207A (ko) 신규한 트리아졸로-피리딘 화합물
KR20090018883A (ko) 암치료용 히스톤 탈아세틸화 효소 저해제로서 엔-히드록시-3-(4-[3-페닐-에스-옥소-프로페닐]-페닐)-아크릴아미드 유도체 및 그 관련 화합물
CN103732592A (zh) 胰岛素样生长因子-1受体抑制剂
JPH0776586A (ja) ピリジン化合物
DE69931163T2 (de) N,n-substituierte cyclische aminderivate
WO2023005267A1 (zh) 一种苯并[b]硒吩类STING调控剂、其制备方法及用途
MX2010013842A (es) Naftiridinonas como inhibidores de aurora cinasa.
RU2606635C2 (ru) Новое соединение, проявляющее ингибиторную активность в отношении parp
KR20140023332A (ko) 티에노〔２，３­ｄ〕피리미딘 유도체 및 부정맥을 치료하기 위한 이의 용도
WO2017034377A1 (en) Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
JP2023510746A (ja) Ｓｍａｒｃａ２－ｖｈｌ分解剤